Literature DB >> 33844177

Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation.

Nemin Chen1, Nico Gabriel2, Maria M Brooks1, Inmaculada Hernandez3.   

Abstract

BACKGROUND: Oral anticoagulation (OAC) is recommended to reduce the risk of stroke or systemic thromboembolism (TE) in atrial fibrillation (AF). In this study, we applied novel joint latent class mixed models to identify heterogeneous patterns of trajectories of OAC use and determined how these trajectories are associated with risks of thromboembolic outcomes. METHODS AND
RESULTS: We used 2013-2016 claims data from a 5% random sample of Medicare beneficiaries, obtained from the Centers for Medicare and Medicaid Services. Our study sample included 16,399 patients newly diagnosed with AF in 2014-2015 who were followed for 12 months after the first AF diagnosis and filled at least one OAC prescription in this time period. OAC use was defined as the number of days covered with OACs every 30-day interval after the first AF diagnosis. We used a joint latent class mixed model to simultaneously evaluate the longitudinal patterns of OAC use and time to stroke or TE, while adjusting for age, race, CHAD2S2-VASc score and HAS-BLED score. Five classes of OAC use patterns were identified: late users (17.8%); late initiators (12.5%); early discontinuers (18.6%); late discontinuers (15.4%); and continuous users (35.6%). Compared with continuous users, the risk of stroke or TE was higher for participants in the late initiators (hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.49-2.01) and late discontinuers (HR 1.23, 95% CI 1.04-1.45) classes.
CONCLUSION: Late initiators and late discontinuers had a higher risk of stroke or TE than continuous users. Early initiation and continuous OAC use is important in preventing stroke and TE among patients diagnosed with AF.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33844177      PMCID: PMC8440356          DOI: 10.1007/s40256-021-00476-8

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  20 in total

1.  Estimation of linear mixed models with a mixture of distribution for the random effects.

Authors:  Cécile Proust; Hélène Jacqmin-Gadda
Journal:  Comput Methods Programs Biomed       Date:  2005-05       Impact factor: 5.428

2.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

3.  Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.

Authors:  Andreas Clemens; Sebastian Haertter; Jeffrey Friedman; Martina Brueckmann; Joachim Stangier; Joanne van Ryn; Thorsten Lehr
Journal:  Curr Med Res Opin       Date:  2012-01-23       Impact factor: 2.580

4.  Latent Classes of Adherence to Oral Anticoagulation Therapy Among Patients With a New Diagnosis of Atrial Fibrillation.

Authors:  Nemin Chen; Maria M Brooks; Inmaculada Hernandez
Journal:  JAMA Netw Open       Date:  2020-02-05

5.  Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.

Authors:  Inmaculada Hernandez; Yuting Zhang; Samir Saba
Journal:  Am J Cardiol       Date:  2017-08-08       Impact factor: 2.778

6.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

Review 7.  Stroke prevention in atrial fibrillation.

Authors:  Ben Freedman; Tatjana S Potpara; Gregory Y H Lip
Journal:  Lancet       Date:  2016-08-20       Impact factor: 79.321

8.  Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation.

Authors:  Inmaculada Hernandez; Meiqi He; Maria M Brooks; Samir Saba; Walid F Gellad
Journal:  Am J Cardiovasc Drugs       Date:  2020-04       Impact factor: 3.571

9.  Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis.

Authors:  Kathleen Lang; Duygu Bozkaya; Aarti A Patel; Brian Macomson; Winnie Nelson; Gary Owens; Samir Mody; Jeff Schein; Joseph Menzin
Journal:  BMC Health Serv Res       Date:  2014-07-28       Impact factor: 2.655

10.  Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation.

Authors:  Inmaculada Hernandez; Meiqi He; Nemin Chen; Maria M Brooks; Samir Saba; Walid F Gellad
Journal:  J Am Heart Assoc       Date:  2019-06-13       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.